Research Review2017-01-30T12:50:37+00:00

DSF Research Review

Welcome to DSF’s Research Review! We use this space to keep you up to date on the most exciting studies that are published each month on Dravet syndrome and SCN1A. Each review includes a link to the original abstract or article (where possible), as well as a lay-person’s summary. Have questions? Email Nicole.

Looking for more information on research? Click on the button below to go to a list of pubmed published scientific articles on Dravet syndrome.

Visit Pubmed Website

August 2018

May 2018

March 2018

February 2018

January 2018

November 2017

The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model

By |November 23rd, 2017|Categories: DSF Research Review|Tags: , |

(Hawkins et al. 2017) Benzodiazepines like clobazam and diazepam target GABAA receptors located in the synaptic area of neurons. Other medication families, like neurosteroids, can target GABAA receptors beyond the synapses. In previous work, [...]

October 2017

Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy

By |October 5th, 2017|Categories: DSF Research Review|Tags: , |

(Peigne S, et al. 2017) Although stiripentol has been used to treat patients with Dravet syndrome for several years, its pharmacokinetics (how the body processes the medication after a dose) are not always well [...]

August 2017

July 2017

Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: A review of its benefit-risk profile in a new patient population

By |July 24th, 2017|Categories: DSF Research Review|Tags: , , , |

(Schoonjans AS, et al. 2017). Fenfluramine is currently in a Phase 3 clinical trial for Dravet syndrome sponsored by Zogenix, Inc. While primarily used in the 1980s and 1990s for obesity, there were reports [...]